[Meta-analysis of the combination of warfarin and clopidogrel after coronary stenting in patients with indications for chronic oral anticoagulation].
To investigate the safety and efficacy of dual antithrombotic regimen of warfarin and clopidogrel in patients who underwent coronary stenting and were with chronic oral anticoagulation. Two investigators independently searched Pubmed, Embase and Cochrane for all reported studies, and yielding 6 articles, published before April 2015, enrolling 4 825 patients, follow-up for at least 12 months. Two investigators independently recorded the data regarding interventions and the occurrence of major bleeding, ischemic stroke, myocardial infarction and death. RevMan5.3 was used to do analysis. Patients on dual antithrombotic regimen had insignificant reduction in major bleeding (odds ratio[OR]was 0.73, 95% confidence interval[CI]was from 0.46 to 1.14, and P=0.16) as compared with triple therapy. While the risk of ischemic stroke (OR= 0.78, 95%CI:0.44-1.38, P=0.39), myocardial infarction (OR= 1.19, 95%CI:0.92-1.53, P=0.18) and the overall incidence of death (OR=0.95, 95%CI:0.56-1.60, P=0.84) were also comparable between the two regimens. Dual antithrombotic regimen of warfarin and clopidogrel is comparable to the recommended triple therapy in respect to the prevention of thromboembolic outcomes of MI/ death and ischemic stroke, while the risk of bleeding is similar in those patients with indications for chronic oral anticoagulation undergoing percutaneous coronary intervention with stent implantation.